Galectin Therapeutics Inc.
- Open
- 3.48
- Day high
- 3.55
- Day low
- 3.21
- Prev close
- 3.53
- Volume
- 388K
- Mkt cap
- $347M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- -2.5
- P/S
- —
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$512K over the last 3 months (0 open-market buys, 7 sales)
- 🏛Institutions accumulating (13F)
Galectin Therapeutics Inc. (GALT) is a Healthcare company listed on NASDAQ. The stock is down 4% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 7 sales (SEC Form 4).
Galectin Therapeutics Inc. (GALT) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
GALT earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 14, 2026 | $-0.09 | $-0.14 | -55.6% | — | — |
| May 15, 2026 | $-0.06 | $-0.08 | -33.3% | — | — |
| Mar 31, 2026 | $-0.10 | $-0.08 | +20.0% | — | — |
| Nov 14, 2025 | $-0.11 | $-0.13 | -18.2% | — | — |
| Aug 14, 2025 | $-0.16 | $-0.12 | +25.0% | — | — |
| May 15, 2025 | $-0.20 | $-0.15 | +25.0% | — | — |
| Mar 31, 2025 | $-0.16 | $-0.19 | -18.8% | $36000 | — |
| Nov 14, 2024 | $-0.20 | $-0.18 | +10.0% | — | — |
| May 15, 2024 | $-0.16 | $-0.19 | -18.8% | — | — |
| Mar 29, 2024 | $-0.16 | $-0.16 | +0.0% | $80000 | — |
| Aug 14, 2023 | $-0.21 | $-0.15 | +28.6% | — | — |
| May 15, 2023 | $-0.21 | $-0.19 | +9.5% | — | — |
GALT insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 4, 2026 | Uihlein Richard Edirector, 10 percent owner: | Option | 2,550,932 | $4.05 |
| Aug 4, 2026 | Uihlein Richard Edirector, 10 percent owner: | Option | 31,825,235 | $3.00 |
| Aug 4, 2026 | Uihlein Richard Edirector, 10 percent owner: | Option | 0 | $3.00 |
| Jul 16, 2026 | Jamil Khurramofficer: Chief Medical Officer | Sell | 16,250 | $5.13 |
| Jul 16, 2026 | Jamil Khurramofficer: Chief Medical Officer | Option | 16,250 | $3.04 |
| Jun 30, 2026 | Jamil Khurramofficer: Chief Medical Officer | Option | 47,467 | $2.50 |
| Jun 30, 2026 | Shlevin Harold H.director | Option | 22,268 | $1.23 |
| Jun 30, 2026 | Jamil Khurramofficer: Chief Medical Officer | Sell | 2,533 | $5.00 |
| Jun 30, 2026 | Jamil Khurramofficer: Chief Medical Officer | Option | 2,037 | $2.20 |
| Jun 30, 2026 | Shlevin Harold H.director | Sell | 22,268 | $5.04 |
| Jun 30, 2026 | Jamil Khurramofficer: Chief Medical Officer | Option | 2,533 | $2.50 |
| Jun 30, 2026 | Shlevin Harold H.director | Sell | 7,732 | $5.00 |
| Jun 30, 2026 | Jamil Khurramofficer: Chief Medical Officer | Sell | 47,467 | $5.04 |
| Jun 30, 2026 | Shlevin Harold H.director | Option | 7,732 | $1.23 |
| Jun 25, 2026 | Jamil Khurramofficer: Chief Medical Officer | Option | 7,557 | $1.23 |
Source: GALT SEC Form 4 filings, latest Aug 4, 2026. For informational purposes only — not investment advice.
See the full GALT insider & 13F page →Galectin Therapeutics Inc. company profile
Overview
Galectin Therapeutics Inc. (NASDAQ:GALT) is a clinical-stage biopharmaceutical company founded in 2000 and headquartered in Norcross, Georgia. Originally incorporated as Pro-Pharmaceuticals, Inc., the company changed its name to Galectin Therapeutics in May 2011 to reflect its focus on developing therapies that target galectin proteins. The company went public in 2002 and has spent over two decades developing treatments for fibrotic diseases, cancer, and other conditions through its specialized approach of inhibiting galectin-3, a protein involved in inflammation and tissue scarring processes.
Business
Galectin Therapeutics operates in the biotechnology sector, specifically focusing on developing drugs that target galectin proteins - naturally occurring molecules that play crucial roles in cell-to-cell communication, inflammation, and tissue repair processes. When galectin proteins become overactive, they can contribute to excessive scarring (fibrosis) in organs like the liver, heart, lungs, and kidneys, as well as promote cancer progression. The company's primary focus is on galectin-3 inhibition, which involves blocking the activity of galectin-3 protein to prevent or reverse harmful tissue scarring and inflammation. Their lead product candidate is belapectin (formerly known as GR-MD-02), a complex carbohydrate polymer derived from citrus pectin that acts as a galectin-3 inhibitor. Belapectin is currently in Phase III clinical trials for treating liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis - conditions where the liver becomes scarred due to fat accumulation and inflammation. Beyond liver disease, Galectin Therapeutics is developing belapectin for multiple therapeutic areas including cancer treatment, psoriasis (an autoimmune skin condition), and fibrosis affecting the lungs and kidneys. The company also has GM-CT-01 in preclinical development for cardiac and vascular fibrosis, targeting heart and blood vessel scarring. Through its joint venture called Galectin Sciences LLC (co-owned with SBH Sciences, Inc.), the company is also researching small molecule inhibitors of galectin-3 that could be administered orally, potentially offering more convenient treatment options compared to intravenous therapies. As a clinical-stage company, Galectin Therapeutics currently generates no commercial revenue and operates entirely on research and development activities funded through equity financing and partnerships.
Revenue model
As a clinical-stage biopharmaceutical company, Galectin Therapeutics currently generates no revenue from product sales, as evidenced by zero revenue across all reported periods. The company operates on a research and development model funded primarily through equity financing, including public offerings and private placements of its common stock. The company's future revenue model will depend on successfully advancing its drug candidates through clinical trials and obtaining regulatory approval. Once approved, Galectin Therapeutics would generate revenue through pharmaceutical product sales to healthcare providers, hospitals, and specialty pharmacies. The primary paying customers would be healthcare systems, insurance companies, and patients (through co-pays) who require treatment for liver fibrosis, cancer, and other fibrotic conditions. Given the specialized nature of galectin-3 inhibitors and the serious medical conditions they target, approved products would likely command premium pricing typical of specialty pharmaceuticals. The company may also pursue licensing agreements with larger pharmaceutical companies, which could provide upfront payments, milestone payments during development, and royalties on future sales. Several factors could significantly impact the company's future profitability margins. Regulatory approval risks represent the primary challenge, as clinical trials may fail to demonstrate efficacy or safety, requiring additional costly studies. Manufacturing costs for complex carbohydrate polymers like belapectin could be substantial, particularly for the specialized production processes required. Competition from larger pharmaceutical companies developing alternative treatments for liver fibrosis and cancer could pressure pricing and market share. Conversely, factors that could improve margins include successful clinical outcomes leading to accelerated approval pathways, potential orphan drug designations for rare fibrotic conditions, and the development of more cost-effective oral formulations through the Galectin Sciences joint venture.
Competitive moat
Galectin Therapeutics operates in a highly competitive biotechnology landscape with limited sustainable competitive advantages at this stage of development. The company's primary potential moat lies in its specialized expertise in galectin-3 inhibition and its proprietary belapectin compound, which represents over two decades of research and development in this specific therapeutic approach. However, this moat is relatively narrow and vulnerable. The company's intellectual property portfolio around galectin-3 inhibitors provides some protection, but patent exclusivity is time-limited and may not prevent competitors from developing alternative approaches to treat the same conditions. Larger pharmaceutical companies with substantially greater resources are actively developing competing treatments for liver fibrosis and cancer, including companies like Gilead Sciences, Bristol Myers Squibb, and Novartis, which have advanced programs targeting NASH and liver fibrosis through different mechanisms. The company's competitive position is further weakened by its limited financial resources compared to major pharmaceutical companies, which constrains its ability to conduct large-scale clinical trials, pursue multiple indications simultaneously, or weather development setbacks. Additionally, the regulatory pathway for liver fibrosis treatments remains challenging, with the FDA requiring robust evidence of clinical benefit, creating execution risk that could allow better-funded competitors to reach market first. The most significant potential disruption could come from breakthrough therapies that address liver fibrosis through entirely different mechanisms, such as gene therapy, cell therapy, or novel small molecule approaches that prove more effective or safer than galectin-3 inhibition. Given these factors, Galectin Therapeutics currently lacks a strong defensive moat and faces substantial competitive and execution risks that could undermine its market position even if its lead programs succeed.
Risks & safety
Galectin Therapeutics presents significant financial risks with a very narrow margin of safety, reflecting the high-risk nature of clinical-stage biotechnology investments. • Cash burn and solvency risk: The company burned approximately $42 million in operating cash flow during 2024, with only $7.4 million in cash remaining as of Q1 2025, indicating less than two quarters of runway at current burn rates • Debt burden: Total liabilities of $122 million significantly exceed total assets of $9.5 million, creating a severely overleveraged balance sheet with negative equity of approximately $112 million • Current ratio: Extremely poor liquidity position with current ratio of 0.08, meaning current liabilities exceed current assets by more than 12-to-1 • Valuation concerns: Trading at negative book value with price-to-book ratio of -0.68, reflecting the company's insolvent balance sheet position • Going concern risk: The combination of minimal cash reserves, high burn rate, and negative equity creates immediate going concern issues requiring urgent equity financing to continue operations The company faces imminent financial distress and will likely need to raise capital through highly dilutive equity offerings or risk bankruptcy, making this investment extremely speculative with potential for total loss.
Recent development
Based on the available financial data, Galectin Therapeutics has maintained focus on advancing its lead compound belapectin through clinical development, particularly for liver fibrosis applications. The company appears to be progressing its Phase III clinical trial for belapectin in treating liver fibrosis associated with NASH cirrhosis, which represents the most advanced and potentially valuable program in its pipeline. The company has continued developing its broader pipeline of galectin-3 inhibitor applications, including treatments for cancer, psoriasis, and fibrotic conditions affecting multiple organs. Through its joint venture Galectin Sciences LLC, the company has been working on developing oral formulations of galectin-3 inhibitors, which could provide significant competitive advantages over intravenous therapies in terms of patient convenience and treatment compliance. However, the company's development activities have been constrained by its deteriorating financial position. The dramatic decline in cash reserves from over $27 million in mid-2024 to just $7.4 million by Q1 2025 suggests the company has had to prioritize spending on its most critical programs while potentially delaying or scaling back other development activities. The company has likely been focused on completing key clinical milestones for belapectin while seeking additional financing to continue operations, as evidenced by the significant increase in total liabilities and the need for ongoing equity financing to fund clinical trials and regulatory activities.
GALT company profile · for informational purposes only — not investment advice.
Track GALT with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free